Your session is about to expire
← Back to Search
Combination Immunotherapy for Human Papillomavirus Cancers
Study Summary
This trial is testing a combination of immunotherapy drugs to see if they can help people with HPV-associated cancers.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 1 & 2 trial • 21 Patients • NCT04247282Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have HIV or Hepatitis with undetectable viral load and stable health.My cancer is HPV-related and in an advanced or metastatic stage.I had severe reactions to previous immunotherapy.I've had one round of chemo and, if approved for my cancer type, checkpoint therapy.I haven't had cancer treatments except for hormone therapy or palliative bone therapy in the last 28 days.I am not pregnant or breastfeeding.I am using or willing to use effective birth control during and for two months after the study.My kidney and liver functions are within the required range.My brain or CNS cancer has been stable for over a month after treatment.I've had one round of chemo and, if approved for my cancer type, checkpoint therapy.I have a mild autoimmune disease or am on low-dose steroids not for immune suppression.I can take care of myself but might not be able to do heavy physical work.I can take care of myself but might not be able to do heavy physical work.Criteria for subjects to be enrolled in the study are that they must have measurable disease according to RECIST 1.1 guidelines.My condition is anal cancer.I am willing to accept blood products if needed.I haven't had major surgery in the last 28 days.I haven't had a cancer related to HPV in the last 3 years, except for a local one that's been treated or one not needing active treatment.I have had a severe allergic reaction to monoclonal antibodies.I have not had chemotherapy that weakens my immune system or any organ transplant.I am 18 years old or older.I am 18 years old or older.My cancer is HPV positive and has spread beyond its original location.
- Group 1: Cohort 2, Arm 2: Cervical Cancer With Prior Pelvic Radiation and Boost Brachytherapy
- Group 2: Cohort 1, Arm 1: Human Papillomavirus (HPV) Associated Malignancies
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the maximum capacity of enrollees in this clinical trial?
"Absolutely. According to clinicaltrials.gov, this research project is currently recruiting participants who were first posted on June 9th 2020 and last modified on November 29th 2022. The trial requires the enlistment of 56 individuals from 1 medical centre."
Are individuals currently eligible to partake in this experiment?
"Affirmative. The information available on clinicaltrials.gov attests to the fact that this research endeavour is actively trying to recruit volunteers; it was initially posted on June 9th 2020 and updated lastly November 29th 2022. Specifically, 56 participants are wanted from 1 site for the study's duration."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger